

**WIHS VIROLOGIC REBOUND AND RESISTANCE STUDY  
SCREENING TO DETERMINE CHANGES IN HAART REGIMEN  
VRS 5**

**IMPORTANT: MUST COMPLETE A7 BEFORE TALKING TO PARTICIPANT.**

- A1. PARTICIPANT ID:    |\_|-|\_|\_|-|\_|\_|\_|\_|-|\_|
- A2. FORM VERSION:      $\frac{0}{M}$     $\frac{4}{M}$  /  $\frac{0}{D}$     $\frac{1}{D}$  /  $\frac{0}{Y}$     $\frac{3}{Y}$
- A3. DATE FORM COMPLETED:    $\frac{\quad}{M}$     $\frac{\quad}{M}$  /  $\frac{\quad}{D}$     $\frac{\quad}{D}$  /  $\frac{\quad}{Y}$     $\frac{\quad}{Y}$
- A4. INTERVIEWER'S INITIALS:    \_\_\_   \_\_\_   \_\_\_    A5. WIHS STUDY VISIT #:   \_\_\_   \_\_\_
- A6. CORE VISIT .....1 (GO TO A8a)  
3 MONTH VRS VISIT.....2 (GO TO A8b)

**A7: COMPLETE BEFORE TALKING TO PARTICIPANT:  
CIRCLE CODES OF ALL MEDICATIONS FOR WHICH A VRS 4 WAS COMPLETED AT PARTICIPANT'S LAST VISIT (CORE OR 3 MONTH VRS) IN COLUMN A7 BELOW.**

**A8a. USING ALL DRUG FORMS 1 COMPLETED AT TODAY'S INTERVIEW, CIRCLE CODES OF ALL MEDICATIONS PARTICIPANT REPORTED TAKING CURRENTLY ('YES' TO QUESTION 4A) IN COLUMN A8 BELOW**

**A8b. ASK PARTICIPANT FOR EACH MEDICATION LISTED BELOW:  
Are you currently taking (DRUG)?  
CIRCLE CODES OF THE MEDICATIONS TO WHICH RESPONDENT ANSWERS 'YES' IN COLUMN A8.**

	A7.	A8.
	LASTVISIT	THIS VISIT
<b><u>Nucleoside/Nucleotide RTIs</u></b>		
Epivir (lamivudine, 3-TC )	204	204
Ziagen (abacavir, 1592U89)	218	218
Retrovir (AZT, zidovudine, ZDV)	092	092
Combivir (AZT + 3TC)	227	227
Zerit (stavudine, d4T)	159	159
Hivid (dideoxycytidine, zalcitabine, ddC)	094	094
Videx/ Videx EC (dideoxyinosine, didanosine, ddl)	147	147
Trizivir (abacavir + AZT + 3TC)	240	240
Viread (tenofovir, bis-POC-PMPA)	234	234
Coviracil (emtricitabine, FTC)	239	239
<b><u>Protease Inhibitors</u></b>		
Agenerase (amprenavir ,141W94)	219	219
Crixivan (indinavir)	212	212
Kaletra (lopinavir/ritonavir, ABT-378/r)	217	217
Viracept (nelfinavir)	216	216
Norvir (ritonavir)	211	211
Invirase or Fortovase (saquinavir)	210	210
Atazanavir (BMS-232632)	243	243
Tipranavir (PNU-140690)	238	238

--

	A7. LAST VISIT	A8. THIS VISIT
<b>Non-Nucleoside RTIs</b>		
Rescriptor (delavirdine, U- 90)	194	194
Sustiva (efavirenz , DMP266)	220	220
Viramune (nevirapine)	191	191
<b>Entry Inhibitors</b>		
Fuzeon (T-20, enfuviratide)	233	233
<b>Other</b>		
Droxia or Hydria (hydroxyurea)	207	207
Other antiviral (from Drug List 1)	Code	Code
Name of Drug:	□□□□	□□□□

A11. DOES PARTICIPANT REPORT CURRENTLY TAKING ANY PI OR NON-NUCLEOSIDE RTIS?

YES.....1  
NO.....2

A12. ARE THE MEDICATIONS CHECKED IN A7 AND A8 DIFFERENT?

YES.....1  
NO.....2

**A11 = 1 AND A12 = 1:**

1. 2 HOUR PK SAMPLING IS INDICATED
2. IF THIS IS A CORE VISIT, CONDUCT A CORE 2 HOUR PK VISIT WITHIN THE NEXT TWO WEEKS
3. IF THIS IS A 3 MONTH VRS VISIT, CONDUCT A 3 MONTH 2 HOUR PK VISIT.
4. OBTAIN MEDICATION RECORDS RELEASE AND CONTACT PROVIDER TO COMPLETE VRS 6.

**A11 = 1 AND A12 = 2:**

1. 2 HOUR PK SAMPLING IS NOT INDICATED
2. IF THIS IS A CORE VISIT, COMPLETE VRS 3 AND VRS 4. (CORE NON-PK VISIT)
3. IF THIS IS A 3 MONTH VRS VISIT, CONDUCT A 3 MONTH RANDOM PK VISIT.

**A11=2 AND A12=1:**

1. NO PK SAMPLING TO BE DONE
2. IF THIS IS A CORE VISIT, COMPLETE VRS 3 AND VRS 4. (CORE NON-PK VISIT)
3. IF THIS IS A 3 MONTH VRS VISIT, CONDUCT A 3 MONTH NON PK VISIT.
4. OBTAIN MEDICATION RECORDS RELEASE AND CONTACT PROVIDER TO COMPLETE VRS 6.

**A11=2 AND A12=2:**

1. NO PK SAMPLING TO BE DONE
2. IF THIS IS A CORE VISIT, COMPLETE VRS 3 AND VRS 4. (CORE NON-PK VISIT)
3. IF THIS IS A 3 MONTH VRS VISIT, CONDUCT A 3 MONTH NON PK VISIT.